natgillin/translations-raw huggingface dataset:
Clinically relevant CTC toxicities that were reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain. 
Klinično pomembne CTC toksičnosti, o katerih so poročali pri > 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: okužbo brez nevtropenije, febrilno nevtropenijo, alergijsko reakcijo/preobčutljivost, povišan kreatinin, motorično nevropatijo, senzorično nevropatijo, multiformni eritem in bolečino v trebuhu.
Including the induction phase, the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed arm and 13.6 months for the placebo arm, hazard ratio = 0.71 (95% CI = 0.56-0.88, p = 0.002). 
Vključno z indukcijsko fazo je bila mediana skupnega preživetja za bolnike z NSCLC, ki nima pretežno ploščatocelične histologije, 18,6 mesecev za skupino s pemetreksedom in 13,6 mesecev za skupino s placebom (razmerje tveganja = 0,71, 95 % CI: 0,56-0,88, p = 0,002).
Method of administration For Precautions to be taken before handling or administering Pemetrexed Pfizer, see section 6.6. 
Za previdnostne varnostne ukrepe pri pripravi in dajanju zdravila Pemetreksed Pfizer glejte poglavje
Pemetrexed Pfizer 1,000mg powder for concentrate for solution for infusion 2 years 
Pemetreksed Pfizer 1.000 mg prašek za koncentrat za raztopino za infundiranje 2 leti
To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. 
Da zmanjšamo incidenco in resnost kožnih reakcij, dajemo kortikosteroid dan pred dajanjem pemetrekseda, na dan dajanja pemetrekseda in naslednji dan. Kortikosteroid naj ustreza 4 mg deksametazona, danega peroralno dvakrat dnevno (glejte poglavje 4.4).
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease. 
Klinično pomembne toksičnosti, o katerih so poročali pri ≥ 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje AST, povišanje ALT, okužbo, febrilno nevtropenijo, odpoved ledvic, pireksijo, dehidracijo, konjunktivitis in znižan očistek kreatinina.
Nephrogenic diabetes insipidus and renal tubular necrosis have been reported in post marketing setting with an unknown frequency. 
V obdobju trženja so z neznano pogostnostjo poročali o nefrogenem diabetesu insipidusu in ledvični tubulni nekrozi.
Clinically relevant CTC toxicity of any grade that was reported in ≥1% and ≤5% of the patients that were randomly assigned to pemetrexed include: febrile neutropenia, infection, decreased platelets, diarrhoea, constipation, alopecia, pruritus/itching, fever (in the absence of neutropenia), ocular surface disease (including conjunctivitis), increased lacrimation, dizziness and motor neuropathy. 
Klinično pomembne CTC toksičnosti, o katerih so poročali pri > 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: febrilno nevtropenijo, infekcijo, znižane trombocite, diarejo, zaprtje, alopecijo, srbenje, vročino (v odsotnosti nevtropenije), bolezni površine očesa (vključno s konjunktivitisom), povečano solzenje, omotico in motorično nevropatijo.
Clinically relevant toxicity that was reported in < 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy. 
Klinično pomembne toksičnosti, o katerih so poročali pri < 1 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje GGT, bolečino v prsnem košu, aritmijo in motorično nevropatijo.
*p-value refers to comparison between arms. 
Okrajšava: IZ = interval zaupanja *p-vrednost se nanaša na primerjavo med vejama zdravljenja.
Reconstitute 100 mg vials with 4.2 ml of sterile water for injections, resulting in a solution containing 25 mg/ml pemetrexed. 
100 mg viale rekonstituirajte s 4,2 ml sterilne vode za injekcije, da dobite raztopino, ki vsebuje 25 mg/ml pemetrekseda.
The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of pemetrexed plus cisplatin first-line induction treatment, the median investigator-assessed PFS was 6.9 months for the pemetrexed arm and 5.6 months for the placebo arm (hazard ratio = 0.59, 95% CI = 0.47-0.74). 
Za naključno izbrane bolnike, merjeno od začetka zdravljenja s pemetreksedom in indukcijskim zdravljenjem prve izbire s cisplatinom, je bilo mediano preživetje brez napredovanja bolezni po oceni raziskovalca 6,9 meseca za skupino, ki je prejemala pemetreksed, in 5,6 meseca za skupino, ki je prejemala placebo (razmerje tveganja = 0,59 95 % IZ = 0,47-0,74).
A white to light yellow or green-yellow lyophilised powder. 
Bel do svetlorumen ali zelenorumen liofilizirani prašek.
Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion Store the 100 mg vial below 30°C. 
Pemetreksed Pfizer 100 mg prašek za koncentrat za raztopino za infundiranje 100 mg vialo shranjujte pri temperaturi do 30 °C.
The median OS for patients with NSCLC other than predominantly squamous cell histology (N = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI = 0.56-0.88, p = 0.002). 
Mediana skupnega preživetja za bolnike z NSCLC, ki nima pretežno ploščatocelične histologije (n = 481), je bila 15,5 mesecev za skupino s pemetreksedom in 10,3 mesecev za skupino s placebom (razmerje tveganja = 0,70, 95 % CI: 0,56-0,88, p = 0,002).
Reconstitute 500 mg vials with 20 ml of sterile water for injections, resulting in a solution containing 25 mg/ml pemetrexed. 
500 mg viale rekonstituirajte z 20 ml sterilne vode za injekcije, da dobite raztopino, ki vsebuje 25 mg/ml pemetrekseda.
In clinical trials, cases of colitis (including intestinal and rectal bleeding, sometimes fatal, intestinal perforation, intestinal necrosis and typhlitis) have been reported uncommonly in patients treated with pemetrexed. 
V kliničnih preskušanjih so pri bolnikih, ki so jih zdravili s pemetreksedom, občasno poročali o primerih kolitisa (vključno s črevesnimi krvavitvami in krvavitvami iz danke, ki so bile včasih usodne, črevesnimi perforacijami, črevesno nekrozo in vnetjem slepega črevesa).
Frequency Event* 
Dogodek*
Pemetrexed Pfizer 500 mg powder for concentrate for solution for infusion 2 years 
Pemetreksed Pfizer 500 mg prašek za koncentrat za raztopino za infundiranje 2 leti
PHARMACEUTICAL FORM AND CONTENTS Powder for concentrate for solution for infusion 500 mg 
prašek za koncentrat za raztopino za infundiranje 500 mg
Reconstitute 1000 mg vials with 40 ml of sterile water for injections resulting in a solution containing 25 mg/ml pemetrexed. 
1.000 mg viale rekonstituirajte s 40 ml sterilne vode za injekcije, da dobite raztopino, ki vsebuje 25 mg/ml pemetrekseda.
Warnings and precautions Talk to your doctor or hospital pharmacist before receiving Pemetrexed Pfizer. 
Pred začetkom uporabe zdravila Pemetreksed Pfizer se posvetujte z zdravnikom ali bolnišničnim farmacevtom.
Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident, and transient ischaemic attack, have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. 
Občasno so v kliničnih študijah pemetrekseda, običajno ob sočasnem dajanju z drugo citotoksično učinkovino, poročali o resnih srčnožilnih in možganskožilnih dogodkih, vključno z miokardnim infarktom, angino pektoris, cerebrovaskularnim insultom in prehodnimi ishemičnimi atakami.
Allergic reaction: skin rash / burning or prickling sensation Infection including sepsis 
Pogosto (pojavijo se lahko pri največ 1 od 10 bolnikov) Alergijske reakcije: kožni izpuščaji/pekoč ali zbadajoč občutek Okužba vključno s sepso
pemetrexed (N = 265) 
Pemetreksed (N = 265)
After reconstitution (see section 6.6), each vial contains 25 mg/ml of pemetrexed. 
Po rekonstituciji ena viala vsebuje 25 mg/ml pemetrekseda.
PHARMACEUTICAL FORM AND CONTENTS Powder for concentrate for solution for infusion 100 mg 
prašek za koncentrat za raztopino za infundiranje 100 mg
9 l/m2. 
100.000 celic/mm
Stomatitis/Pharyngitis Diarrhoea without colostomy 
Diareja brez kolostomije
Pemetrexed Pfizer 500 mg powder for concentrate for solution for infusion Each vial contains 500 milligrams of pemetrexed (as pemetrexed ditromethamine). 
Pemetreksed Pfizer 500 mg prašek za koncentrat za raztopino za infundiranje: Ena viala vsebuje 500 miligramov pemetrekseda (v obliki ditrometaminijevega pemetrekseda).
Leucocytes decreased 53.0 14.9 16.6 Haemoglobin decreased 26.2 4.2 Platelets decreased 
Znižani levkociti 53,0 Znižan hemoglobin Znižani trombociti
Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma Randomised and treated patients Fully supplemented patients 
Učinkovitost pemetrekseda skupaj s cisplatinom v primerjavi s cisplatinom pri malignem plevralnem mezoteliomu
Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion Store below 30°C. 
Pemetreksed Pfizer 100 mg prašek za koncentrat za raztopino za infundiranje Shranjujte pri temperaturi do 30 °C.
Clinically relevant CTC toxicities that were reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain. 
Klinično pomembne CTC toksičnosti, o katerih so poročali pri > 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala cisplatin in pemetreksed, vključujejo: odpoved ledvic, okužbo, pireksijo, febrilno nevtropenijo, povišane AST, ALT in GGT, koprivnico in bolečino v prsnem košu.
Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion Each vial contains 100 milligrams of pemetrexed (as pemetrexed ditromethamine). 
Pemetreksed Pfizer 100 mg prašek za koncentrat za raztopino za infundiranje: Ena viala vsebuje 100 miligramov pemetrekseda (v obliki ditrometaminijevega pemetrekseda).
Pemetrexed Pfizer 1,000 mg powder for concentrate for solution for infusion Each vial contains 1,000 milligrams of pemetrexed (as pemetrexed ditromethamine). 
Pemetreksed Pfizer 1.000 mg prašek za koncentrat za raztopino za infundiranje: Ena viala vsebuje 1.000 miligramov pemetrekseda (v obliki ditrometaminijevega pemetrekseda).
Pemetrexed Pfizer 500 mg powder for concentrate for solution for infusion This medicinal product does not require any special storage conditions. 
Pemetreksed Pfizer 500 mg prašek za koncentrat za raztopino za infundiranje Za shranjevanje zdravila niso potrebna posebna navodila.
Pancytopenia has been uncommonly reported during clinical trials with pemetrexed. 
V kliničnih preskušanjih s pemetreksedom so redko poročali o pancitopeniji.
Common Neuropathy-sensory Taste disturbance 
Pogosto Nevropatija - senzorna
Pemetrexed Pfizer 1,000 mg powder for concentrate for solution for infusion This medicinal product does not require any special storage conditions. 
Pemetreksed Pfizer 1.000 mg prašek za koncentrat za raztopino za infundiranje Za shranjevanje zdravila niso potrebna posebna navodila.
Tabulated list of adverse reactions 
V tabeli prikazani neželeni učinki
Common Conjunctivitis 
POSTOPEK UPORABE
Inflammation of the lining of the oesophagus (gullet) has been experienced with pemetrexed / radiation therapy. 
V kliničnih preskušanjih s pemetreksedom so občasno poročali o ezofagitisu/radiacijskem ezofagitisu.
Parenteral medicines must be inspected visually for particulate matter and discolouration prior to administration. 
Videz parenteralnih zdravil moramo pred dajanjem vizualno pregledati, da ne vsebujejo trdnih delcev ali da nimajo spremenjene barve.
Common Neuropathysensory 
Nevropatijasenzorična
Irritation of the skin and itching Chest pain 
Draženje kože in srbenje
Table 2. 
PRILOGA II
Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is observed. 
Če opazimo nevrološko toksičnost stopnje 3 ali 4, zdravljenje prekinemo.
Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. 
Občasno so v kliničnih študijah pemetrekseda, običajno ob sočasnem dajanju z drugo citotoksično učinkovino, poročali o resnih srčnožilnih dogodkih, vključno z miokardnim infarktom in možganskožilnimi dogodki.
Read the package leaflet for the shelf life of the reconstituted product. 
EXP Za informacije o roku uporabnosti rekonstituiranega zdravila preberite navodilo za uporabo.
NAME OF THE MEDICINAL PRODUCT Pemetrexed Pfizer 1,000 mg powder for concentrate for solution for infusion pemetrexed 
Pemetreksed Pfizer 1.000 mg prašek za koncentrat za raztopino za infundiranje
Uncommon cases of oedema have been reported in patients treated with pemetrexed. 
Pri bolnikih, zdravljenih s pemetreksedom, so poročali o občasnih primerih edema.
Creatinine elevation 
Povišanje
Immunodepressed status is common in cancer patients. 
Pri bolnikih z rakom je delovanje imunskega sistema pogosto oslabljeno.
The active substance is pemetrexed. 
Zdravilna učinkovina je pemetreksed.
Reconstituted and infusion solutions 
za intravensko uporabo po rekonstituciji in redčenju
NAME OF THE MEDICINAL PRODUCT Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion pemetrexed 
Pemetreksed Pfizer 100 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed at a dose of 500 mg/m2 was studied as a single agent in 64 chemonaive patients with malignant pleural mesothelioma. 
Pemetreksed kot edino učinkovino so preučevali v odmerku 500 mg/m2 pri
Sepsis, sometimes fatal, has been commonly reported during clinical trials with pemetrexed. 
V kliničnih preskušanjih s pemetreksedom so pogosto poročali o sepsi, ki je bila včasih usodna.
Pemetrexed Pfizer. 
Shranjevanje zdravila Pemetreksed Pfizer
NAME OF THE MEDICINAL PRODUCT Pemetrexed Pfizer 500 mg powder for concentrate for solution for infusion pemetrexed 
Pemetreksed Pfizer 500 mg prašek za koncentrat za raztopino za infundiranje
Rash/ desquamation Common Pruritus Alopecia 
Pogosto Srbenje Alopecija
Table 3. 
PRILOGA III
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL 1,000 mg 
Nalepka na viali 1.000 mg
Kidney failure 
Odpoved ledvic
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 1,000 mg 
Zunanja škatla 1.000 mg
Breast-feeding 
Stomatitis/ faringitis
GENERAL CLASSIFICATION FOR SUPPLY 15. 
- Navodilo shranite.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 500 mg 
Zunanja škatla 500 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 100 mg 
Zunanja škatla 100 mg
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
Pain in the abdomen 
Bolečina v trebuhu
Common Dyspepsia 
Diareja Bruhanje
Pemetrexed as a single agent 
Pemetreksed kot samostojno zdravilo
Renal Disorders Common Renal disorders**** 
Pogosto Bolezni sečil****
(Invented) name Strength Pharmaceutical Form 
(Izmišljeno) ime Jakost Farmacevtska oblika
Pack size 
matriks z lepilom za
This summary was last updated in 01-2013. 
Povzetek je bil nazadnje posodobljen 01-2013.
106 volunteers completed the study and were included in the results. 
Študijo je zaključilo 106 prostovoljcev, ki so bili vključeni v rezultate.
Doctors will therefore need to use the scans in conjunction with clinical evaluation. 
Zdravniki bodo zato morali uporabiti posnetke skupaj s kliničnim vrednotenjem.
The European Commission granted a marketing authorisation valid throughout the European Union for Amyvid on 14 January 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Amyvid, veljavno po vsej Evropski uniji, odobrila dne 14 januarja 2013.
This is a summary of the European public assessment report (EPAR) for Amyvid. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Amyvid.
The most common side effect with Amyvid (seen in between 1 and 10 patients in 100) is headache. 
Najpogostejši neželeni učinek zdravila Amyvid (opažen pri 1 do 10 bolnikih od 100) je glavobol.
A main study was conducted in 226 volunteers divided into two groups: a group of healthy young people and a group of patients nearing the end of their lives who had consented to autopsies when they died. 
Glavna študija je bila opravljena z 226 prostovoljci, ki so bili razdeljeni v dve skupini: v skupino zdravih mladih oseb in v skupino bolnikov ob koncu življenja, ki so privolili v obdukcijo.
Other information about Amyvid 
Druge informacije o zdravilu Amyvid
What measures are being taken to ensure the safe use of Amyvid? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Amyvid?
Amyvid is for diagnostic use only. 
Zdravilo Amyvid je namenjeno samo za diagnostično uporabo.
The type of scan used with Amyvid is called positron emission tomography (PET). 
Vrsta slikanja, ki se uporablja z zdravilom Amyvid, se imenuje pozitronska emisijska tomografija (PET).
β-amyloid plaques are deposits sometimes present in the brains of people with dementias (such as Alzheimer's disease, Lewy body dementia and Parkinson's disease dementia) and some elderly people with no symptoms. 
β-amiloidne lehe so obloge, ki so včasih prisotne v možganih oseb z demencami (kot so Alzheimerjeva bolezen, demenca z Lewyjevimi telesci in demenca pri Parkinsonovi bolezni) ter pri nekaterih asimptomatskih starejših osebah.
In addition, the usefulness of Amyvid in predicting the development of Alzheimer's disease in patients with memory problems or in monitoring patients' response to treatment has not been established. 
Poleg tega uporabnost zdravila Amyvid pri napovedovanju razvoja Alzheimerjeve bolezni pri bolnikih, ki imajo težave s spominom, ali pri spremljanju odzivov bolnikov na zdravljenje ni bila ugotovljena.
Amyvid must not be used in people who are hypersensitive (allergic) to florbetapir (18F) or any of the other ingredients. 
Zdravila Amyvid ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) florbetapir (18F) ali katero koli drugo sestavino zdravila.
The specificity of the PET scans was 100% in 47 healthy volunteers, which means that all of their scans were rated as negative after being read by experts who were not aware if the scans belonged to healthy people or to patients. 
Specifičnost preiskav PET je bila pri 47 zdravih prostovoljcih 100-odstotna, kar pomeni, da so bili vsi njihovi posnetki ocenjeni kot negativni, ko so jih odčitali strokovnjaki, ki niso vedeli, ali gre za posnetke zdravih oseb ali bolnikov.
When the results of the autopsies were compared with the PET scans, the scans were shown to have a sensitivity of 92% and a specificity of 100%. 
Ko so primerjali rezultate obdukcij s preiskavami PET, so ugotovili 92odstotno občutljivost in 100-odstotno specifičnost preiskav.
The effects of Amyvid were first tested in experimental models before being studied in humans. 
Učinki zdravila Amyvid so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The study looked at sensitivity and specificity of the scans (how reliable they were at differentiating volunteers who had significant amounts of plaques in the brain from those who did not). 
V študiji so proučevala občutljivost in specifičnost posnetkov (s kakšno zanesljivostjo ločijo prostovoljce z večjimi količinami leh v možganih od tistih prostovoljcev, ki jih nimajo).
What benefit has Amyvid shown during the studies? 
Kakšne koristi je zdravilo Amyvid izkazalo med študijami?
Patients should discuss the results of their PET scan with their doctor. 
Bolniki naj se o rezultatih svoje preiskave PET pogovorijo z zdravnikom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Amyvid. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Amyvid, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Amyvid is a solution for injection that contains the active substance florbetapir ( 
Amyvid je raztopina za injiciranje, ki vsebuje zdravilno učinkovino florbetapir (
PET scans with Amyvid should only be requested by doctors skilled in the clinical management of patients with neurodegenerative diseases such as Alzheimer's and other dementias. 
Preiskave PET z zdravilom Amyvid lahko naročijo le zdravniki, ki so usposobljeni za klinično obravnavo bolnikov z nevrodegenerativnimi boleznimi, kot so Alzheimerjeva in druge demence.
This means that the PET scans were able to correctly identify as positive 92% of the patients who had significant amounts of plaques, and that all patients without significant plaques were correctly rated as negative. 
To pomeni, da so s preiskavami PET kot pozitivne pravilno identificirali 92 % bolnikov, ki so imeli večje količine leh, in da so bili vsi bolniki brez večjih količin leh pravilno ocenjeni negativno.
Amyvid is given by injection into a vein about 30 to 50 minutes before obtaining an image from a PET scan. 
Zdravilo Amyvid se injicira intravensko približno 30 do 50 minut pred izdelavo slike z aparatom za pozitronsko emisijsko tomografijo.
The company that markets Amyvid will provide access to a training course for all nuclear medicine physicians expected to use this product in the EU in order to ensure accurate and reliable reading of the PET scan images. 
Družba, ki trži zdravilo Amyvid, bo vsem zdravnikom specialistom nuklearne medicine, za katere se pričakuje, da bodo zdravilo uporabljali v EU, omogočila dostop do programa usposabljanja, da se bo tako zagotovilo natančno in zanesljivo odčitavanje slik preiskav PET.
The active substance in Amyvid, florbetapir ( 
Zdravilna učinkovina v zdravilu Amyvid, florbetapir (
F), is a radiopharmaceutical that emits low amounts of radiation and works by targeting and attaching to β-amyloid plaques in the brain. 
F), je radiofarmak, ki oddaja majhne količine sevanja in deluje tako, da se veže na β-amiloidne lehe v možganih.
A negative scan indicates sparse or no β-amyloid plaques, which means that the patient is unlikely to have Alzheimer's disease. 
Negativen rezultat preiskave kaže na redke ali odsotne β-amiloidne lehe, kar pomeni, da je malo verjetno, da ima bolnik Alzheimerjevo bolezen.
This is regarded as a significant improvement in the diagnosis of patients with memory problems who are being evaluated for Alzheimer's disease and other neurodegenerative diseases. 
To ocenjujemo kot bistveno izboljšavo diagnostike bolnikov, ki imajo težave s spominom in pri katerih ugotavljamo morebitno Alzheimerjevo bolezen in druge nevrodegenerativne bolezni.
What is the risk associated with Amyvid? 
Kakšna tveganja so povezana z zdravilom Amyvid?
Amyvid delivers a very low amount of radiation with minimal risk of cancer or any hereditary abnormalities. 
Zdravilo Amyvid povzroča majhne količine sevanja, povezanega z najmanjšim tveganjem za razvoj raka ali dednih nenormalnosti.
A positive scan on its own, however, is not sufficient to make a diagnosis in patients with memory problems, as plaque deposition may be seen in patients with different types of neurodegenerative dementias as well as in elderly people with no symptoms. 
Pozitiven rezultat preiskave sam po sebi ne zadošča za postavitev diagnoze pri bolnikih, ki imajo težave s spominom, saj je odlaganje leh lahko prisotno pri bolnikih z različnimi vrstami nevrodegenerativnih demenc in tudi pri asimptomatskih starejših osebah.
Why has Amyvid been approved? 
Zakaj je bilo zdravilo Amyvid odobreno?